Labcorp
Our global life sciences company brings diagnostic testing & drug development together.
Alert:
Labcorp has multiple COVID-19 testing options. Learn more >>>
Synonyms
- Opdivo®
- Programmed Death Ligand 1
Special Instructions
Note: This test number is used for tracking oncology IHC specimens to the laboratory. Bill codes will be added when testing is complete, based on the processes performed in the laboratory.
Expected Turnaround Time
5 - 9 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
|
|
|
5 - 9 days |
Specimen Requirements
Specimen
Tissue
Volume
One formalin-fixed paraffin-embedded (FFPE) tissue block or five unstained positively charged slides sectioned from FFPE tissue block at 4 to 5 microns.
Minimum Volume
Three unstained tissue slides
Collection
Tissue should be fixed in 10% neutral buffered formalin for no more than 72 hours. Embed in paraffin.
Storage Instructions
Room temperature
Causes for Rejection
Insufficient tissue; tumor other than non-small-cell lung cancer
|
Insufficient tissue; tumor other than non-small-cell lung cancer Insufficient tissue; tumor other than non-small-cell lung cancer |
|
Insufficient tissue; tumor other than non-small-cell lung cancer Insufficient tissue; tumor other than non-small-cell lung cancer |
Test Details
Methodology
Immunohistochemistry (IHC)
References
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-1639.26412456
Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non−small-cell lung cancer. N Engl J Med. 2015 Jul 9; 373(2):123-135.26028407
Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non−small-cell lung cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012.25897158
Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031.31562796
Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Chicago, Ill; Annual Meeting of the American Society of Clinical Oncology; 2015. Abstract LBA109.
Sundar R, Cho BC, Brahmer JR, Soo R. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.25755681
|
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-1639.26412456 Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non−small-cell lung cancer. N Engl J Med. 2015 Jul 9; 373(2):123-135.26028407 Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non−small-cell lung cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012.25897158 Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031.31562796 Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Chicago, Ill; Annual Meeting of the American Society of Clinical Oncology; 2015. Abstract LBA109. Sundar R, Cho BC, Brahmer JR, Soo R. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.25755681 Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-1639.26412456 Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non−small-cell lung cancer. N Engl J Med. 2015 Jul 9; 373(2):123-135.26028407 Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non−small-cell lung cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012.25897158 Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031.31562796 Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Chicago, Ill; Annual Meeting of the American Society of Clinical Oncology; 2015. Abstract LBA109. Sundar R, Cho BC, Brahmer JR, Soo R. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.25755681 |
|
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-1639.26412456 Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non−small-cell lung cancer. N Engl J Med. 2015 Jul 9; 373(2):123-135.26028407 Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non−small-cell lung cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012.25897158 Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031.31562796 Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Chicago, Ill; Annual Meeting of the American Society of Clinical Oncology; 2015. Abstract LBA109. Sundar R, Cho BC, Brahmer JR, Soo R. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.25755681 Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-1639.26412456 Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non−small-cell lung cancer. N Engl J Med. 2015 Jul 9; 373(2):123-135.26028407 Gettinger SN, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non−small-cell lung cancer. J Clin Oncol. 2015 Jun 20; 33(18):2004-2012.25897158 Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019 Nov 21;381(21):2020-2031.31562796 Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Chicago, Ill; Annual Meeting of the American Society of Clinical Oncology; 2015. Abstract LBA109. Sundar R, Cho BC, Brahmer JR, Soo R. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol. 2015 Mar;7(2):85-96.25755681 |
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480578 | Result | 83055-4 | |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480579 | % Tumor Cells Staining: | % | 83053-9 |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480584 | Comments: | 77202-0 | |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480586 | Interpretation: | 77202-0 | |
| 480588 | PD-L1 IHC, OPDIVO(R) | 85148-5 | 480587 | Director Review | 72486-4 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf